GlassScriptPhysician profile
Nickpreet Singh
NPI 1740770098
$2,506.74
in general payments reported to CMS, 2019-2025
10 companies · $558 in 2025
The $558 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $418 · 2022: $494 · 2023: $423 · 2024: $615 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.84 |
| Education | $230.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $807.21 | 2021-2025 | Abre, Onyx Frontier, Resolute Onyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $614.30 | 2021-2023 | Jardiance |
| Stryker Corporation | $365.39 | 2025 | Flowtriever, Clottriever Bold Catheter |
| Boston Scientific Corporation | $176.67 | 2021-2025 | General - Vascular Access |
| Abiomed | $143.49 | 2024 | Impella |
| Gilead Sciences, INC. | $125.00 | 2023 | Epclusa |
| Chiesi USA, INC. | $103.96 | 2023 | Kengreal |
| Amgen INC. | $74.70 | 2022-2024 | Repatha |
| Biotronik INC. | $71.73 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nickpreet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.